Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Fate Therapeutics Inc’s stock clocked out at $3.95, down -2.23% from its previous closing price of $4.04. In other words, the price has decreased by -$2.23 from its previous closing price. On the day, 3.16 million shares were traded. FATE stock price reached its highest trading level at $4.13 during the session, while it also had its lowest trading level at $3.91.
Ratios:
To gain a deeper understanding of FATE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.48 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.
On January 24, 2023, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $115 to $7.
Wedbush Downgraded its Outperform to Neutral on January 06, 2023, whereas the target price for the stock was revised from $42 to $7.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Dulac Edward J III sold 2,447 shares for $7.77 per share. The transaction valued at 19,013 led to the insider holds 101,479 shares of the business.
Dulac Edward J III sold 1,849 shares of FATE for $9,245 on Jan 29 ’24. The Chief Financial Officer now owns 103,926 shares after completing the transaction at $5.00 per share. On Jan 09 ’24, another insider, Wolchko J Scott, who serves as the President and CEO of the company, sold 14,391 shares for $4.37 each. As a result, the insider received 62,889 and left with 371,248 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 449442848 and an Enterprise Value of 180352160. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.08 while its Price-to-Book (P/B) ratio in mrq is 1.06. Its current Enterprise Value per Revenue stands at 2.839 whereas that against EBITDA is -1.132.
Stock Price History:
The Beta on a monthly basis for FATE is 1.77, which has changed by -0.375 over the last 52 weeks, in comparison to a change of 0.23099434 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $8.83, while it has fallen to a 52-week low of $1.63. The 50-Day Moving Average of the stock is -40.09%, while the 200-Day Moving Average is calculated to be -2.92%.
Shares Statistics:
It appears that FATE traded 2.73M shares on average per day over the past three months and 2848750 shares per day over the past ten days. A total of 113.82M shares are outstanding, with a floating share count of 99.49M. Insiders hold about 12.59% of the company’s shares, while institutions hold 92.66% stake in the company. Shares short for FATE as of 1713139200 were 18921464 with a Short Ratio of 6.92, compared to 1710460800 on 13158420. Therefore, it implies a Short% of Shares Outstanding of 18921464 and a Short% of Float of 20.549999.
Earnings Estimates
The current rating of Fate Therapeutics Inc (FATE) is the result of assessments by 18.0 analysts actively engaged in evaluating its market dynamics.On average, analysts expect EPS of -$0.49 for the current quarter, with a high estimate of -$0.43 and a low estimate of -$0.67, while EPS last year was -$0.19. The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.38 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$1.67 and -$2.62 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.81, with 15.0 analysts recommending between -$1.43 and -$2.12.
